CLOS
ARGS

Compagnie Lombard Odier SCmA’s Argos Therapeutics, Inc. ARGS Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,000
Closed -$4K – 697
2017
Q4 		$4K Buy
+1,000
New +$3.35K ﹤0.01% 633

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Compagnie Lombard Odier SCmA's ARGS Position: Q1 2018 in Review

Compagnie Lombard Odier SCmA sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2018, closing a stake of 1,000 shares — an estimated $4K sold.

Compagnie Lombard Odier SCmA first reported a position in ARGS in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 16 funds tracked by Wall St. Rank hold ARGS as of Q1 2018.

  • Compagnie Lombard Odier SCmA reported no remaining Argos Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 1,000 Argos Therapeutics, Inc. shares in Q1 2018, an estimated $4K.
  • Compagnie Lombard Odier SCmA first reported a position in Argos Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Compagnie Lombard Odier SCmA's Argos Therapeutics, Inc. position peaked at $4K in Q4 2017.
  • 16 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2018.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2018, filed 11 May 2018.